Detalhe da pesquisa
1.
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Lancet
; 392(10165): 2718-2727, 2019 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30409443